Risk factors
Caribou Biosciences (CRBU) risk factors
Item 1A of every Caribou Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks5 new8 dropped18 reworded
Caribou faces Nasdaq delisting risks with its stock price dropping below $1.00.
Filed Mar 05, 2026 - FY2024 10-K risk factors66 risks
Caribou Biosciences faces continuous operating losses with an accumulated deficit of $448.4 million at year-end 2024. The clinical-stage company relies heavily on the success of its novel CRISPR chRDNA genome-editing technologies and allogeneic CAR-T cell therapies. Operations depend on complex manufacturing processes, third-party contractors, and the ability to secure substantial additional financing.
Filed Mar 10, 2025